Akso Health Group Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Linda Wang

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3.1yrs
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	2.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Linda Wang (37 yo)

3.1yrs

Mandato

Ms. Yilin Wang also known as Linda, serves as Chief Executive Officer and Chairwoman of the Board at Akso Health Group (formerly known as Xiaobai Maimai Inc.) since October 18, 2021. She served as Co-Chief...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yilin Wang	CEO & Chairwoman of the Board	3.1yrs	Nessun dato	Nessun dato
Stephen P. Brown	Independent Non-Executive Director	2.6yrs	Nessun dato	Nessun dato
Wenjuan Liu	Director	3.3yrs	Nessun dato	Nessun dato
Gerald T. Neal	Independent Non-Executive Director	2.4yrs	Nessun dato	Nessun dato
Zhe Liu	Independent Non-Executive Director	2.1yrs	Nessun dato	Nessun dato

2.6yrs

Durata media

39yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 8HX non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

Akso Health Group Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Akso Health Group, Annual General Meeting, Apr 30, 2024

Akso Health Group, Annual General Meeting, Jun 19, 2023

Less than half of directors are independent

Less than half of directors are independent

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Now 21% undervalued

Full year 2024 earnings released: US$0.19 loss per share (vs US$0.58 loss in FY 2023)

New minor risk - Financial data availability

Akso Health Group, Annual General Meeting, Apr 30, 2024

AHG Announces Plan to Acquire Online Clinic

New major risk - Shareholder dilution

Akso Health Group announced that it has received $13.974055 million in funding

Akso Health Group Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Akso Health Group Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.85 loss in FY 2022)

New minor risk - Shareholder dilution

Akso Health Group, Annual General Meeting, Jun 19, 2023

First half 2023 earnings released: EPS: US$0.035 (vs US$0.53 loss in 1H 2022)

Full year 2022 earnings released: US$0.85 loss per share (vs US$1.94 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Akso Health Group announced delayed 20-F filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Akso Health Group Announces Board Changes

Akso Health Group Announces Board and Committee Changes

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Akso Health Group(NasdaqGM:AHG) dropped from NASDAQ Composite Index

Full year 2021 earnings released: US$1.94 loss per share (vs US$2.91 loss in FY 2020)

New 90-day high: €3.00

New 90-day high: €2.30

Hexindai Inc. to Report First Half, 2021 Results on Dec 21, 2020

Hexindai Inc., Annual General Meeting, Dec 16, 2020

Hexindai Inc. Launches Elite Influencers Program on Xiaobai Maimai

Hexindai Inc. announced delayed 20-F filing

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media